Media coverage about Sanofi (NYSE:SNY) has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sanofi earned a news sentiment score of 1.90 on their scale. InfoTrie also assigned media coverage about the company an news buzz score of 2 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Sanofi’s score:
- Sanofi (SNY) Price Target Raised to $50.00 at Argus (americanbankingnews.com)
- Regulus Therapeutics (RGLS) Stock: Gaining Big On SNY Deal Update (cnafinance.com)
- Regulus Therapeutics (RGLS) Announces Restructuring of Sanofi (SNY) Collaboration (streetinsider.com)
- Sanofi (SNY) Getting Somewhat Favorable Media Coverage, Analysis Finds (americanbankingnews.com)
- Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus (zacks.com)
Several research firms have recently weighed in on SNY. Argus lifted their target price on shares of Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. ValuEngine upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Finally, Wolfe Research began coverage on shares of Sanofi in a research note on Tuesday, October 23rd. They issued a “market perform” rating for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and an average target price of $49.50.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.98 by $0.09. The firm had revenue of $9.39 billion during the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.71 EPS. As a group, research analysts anticipate that Sanofi will post 3.09 earnings per share for the current year.
In other news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/11/08/somewhat-favorable-press-coverage-very-unlikely-to-affect-sanofi-sny-stock-price.html.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.